Georgian Scientists
ქართველი მეცნიერები
Vol. 7 Issue 4, 2025
https://doi.org/10.52340/gs.2025.07.04.42



The Manifestation of Features of Gene Therapy Advances: A Comprehensive Discourse of Current Progress and Future Directions

Nodar Sulashvili[1], Naira Chichoyan[2], Vira Kravchenko[3], Irina Imerlishvili[4], Luiza Gabunia[5], Nana Gorgaslidze[6], Maka Buleishvili[7], Marika Sulashvili[8], Rajkaran Singh[9], Deva Harsha Uday Gundluru[10], David Aphkhazava[11]

1. MD, PhD, Doctor of Pharmaceutical and Pharmacological Sciences in Medicine, Invited Lecturer (Invited Professor) of Scientific Research-Skills Center at Tbilisi State Medical University; Professor of Medical Pharmacology of Faculty of Medicine at Georgian National University SEU; Professor of Medical and Clinical Pharmacology of International School of Medicine at Alte University; Tbilisi, Georgia; Orcid https://orcid.org/0000-0002-9005-8577; E-mail: n.sulashvili@ug.edu.ge
2. MD, PhD, Doctor of Pharmaceutical Sciences, Professor of Yerevan State Medical University After Mkhitar Heratsi, Head of the Department of Pharmacognosy, Yerevan, Armenia. https://orcid.org/0000-0003-3905-3372
3. MD, PhD, Doctor of Biological Sciences, Academician, Professor, Head of The Biological Chemistry Department at National University of Pharmacy of Ukraine, Kharkiv, Ukraine. https://orcid.org/0000-0001-6335-2490
4. PhD, Doctor of Law, Professor, Rector of BAU International University Batumi; Professor of BAU International University Batumi; Professor at the International Black Sea University, Batumi-Tbilisi, Georgia;
5. MD, PhD, Doctor of Medical Sciences, Professor, Director of the Scientific Research-Skills Center at Tbilisi State Medical University, Professor, Head of the Department of Medical and Clinical Pharmacology at Tbilisi State Medical University, Clinical Pharmacologist of The First University Clinic of TSMU, Tbilisi, Georgia; https://orcid.org/0000-0003-0856-2684
6. MD, PhD, Doctor of Pharmaceutical Sciences, Academician, Professor of Tbilisi State Medical University, Head of The Department of Social and Clinical Pharmacy, Tbilisi, Georgia; https://orcid.org/0000-0002-4563-5224
7. MD, PhD, Doctor of Medical Sciences, Professor, Dean of Faculty of Medicine of BAU International University Batumi, Professor of Faculty of Medicine at European University, Professor of Faculty of Medicine at Georgian National University SEU, Professor of Faculty of Medicine at Sulkhan-Saba Orbeliani University, Invited Professor of Faculty of Healthcare Sciences at East European University, Invited Professor of Faculty of Medicine at Caucasus International University, Invited Lecturer of Tbilisi State Medical University, Tbilisi, Georgia; https://orcid.org/0009-0004-2657-8473
8. MD, Doctor of Family Medicine, Invited Lecturer of Tbilisi State Medical University, Department of Molecular and Medical Genetics; Invited Lecturer of Family Medicine of Faculty of Medicine at Georgian National University SEU; Invited Professor of Biochemistry and Molecular and Medical Genetics at The University of Georgia; Tbilisi, Georgia;
9. MD student of Medical Doctor Degree Program of Faculty of Medicine at Georgian National University SEU; Tbilisi, Georgia; https://orcid.org/0009-0000-4903-0145
10. MD student of Medical Doctor Degree Program of Faculty of Medicine at University of Georgia, Tbilisi, Georgia;
11. PhD, Doctor of Biological Sciences, Invited Professor of Biochemistry of University of Georgia, Tbilisi Georgia; Orcid: https://orcid.org/0000-0001-6216-6477

Abstract

Gene therapy has emerged as one of the most transformative approaches in modern medicine, transitioning from a promising experimental concept to an established clinical reality. This comprehensive article examines the current state of gene therapy advances as of 2024-2025, focusing on recent regulatory approvals, clinical trial developments, and technological innovations. The past two years have witnessed unprecedented progress, including the first CRISPR-based therapy approval (Casgevy), expansion of CAR-T cell therapies beyond hematological malignancies, and the development of personalized in vivo gene editing treatments. In 2024 alone, seven novel cell and gene therapy products received FDA approval, marking significant firsts in the field: the first tumor-infiltrating lymphocyte (TIL) therapy, the first T-cell receptor (TCR) therapy, and the first

mesenchymal stem cell product in the United States. The clinical pipeline has expanded dramatically, with over 250 CRISPR clinical trials active globally and approximately 3,500 gene, cell, and RNA therapies in various stages of development. Major therapeutic advances span multiple disease areas including blood disorders, cardiovascular disease, cancers, rare genetic conditions, diabetes, and autoimmune disorders. Despite these remarkable achievements, the field faces challenges including high treatment costs, manufacturing complexities, immunogenicity concerns, and recent reductions in venture capital investment and government research funding. This article provides a comprehensive analysis of current gene therapy modalities, clinical outcomes, emerging technologies, and translational challenges, while projecting future directions for this rapidly evolving therapeutic landscape. The development and refinement of viral vector platforms, particularly adeno-associated virus and lentiviral systems, have been central to clinical success. AAV vectors have demonstrated favorable safety profiles, tissue-specific tropism, and durable transgene expression in post-mitotic tissues, enabling effective in vivo therapies for conditions such as inherited retinal dystrophies, hemophilia, and neuromuscular disorders. Lentiviral vectors, optimized for safety and stable genomic integration, have become the cornerstone of ex vivo gene therapy approaches, supporting long-term correction of hematopoietic stem cells and immune cells. These platforms have enabled curative or near-curative outcomes in monogenic blood disorders and have underpinned the clinical success of engineered cell therapies. The advent of genome editing technologies, most notably CRISPR-Cas systems, has further expanded the therapeutic scope of gene therapy by enabling precise modification of endogenous DNA. Genome editing allows direct correction of pathogenic mutations, targeted gene disruption, and modulation of gene expression, marking a conceptual shift from gene addition toward permanent genetic repair. The clinical approval of CRISPR-based therapies and the rapid translation of engineered T-cell therapies, such as chimeric antigen receptor T-cell therapy, illustrate the growing feasibility and impact of these approaches across oncology, hematology, and emerging non-malignant indications. Emerging next-generation tools, including base editors and prime editors, further enhance precision while potentially reducing off-target effects and genotoxic risk.
Keywords: Gene therapy, CRISPR-Cas9, CAR-T cell therapy, adeno-associated virus (AAV), gene editing, cell therapy, clinical trials, personalized medicine, rare diseases, regenerative medicine

Introduction

Gene therapy represents a transformative paradigm shift in medicine, offering the potential to address diseases at their molecular origins rather than merely ameliorating symptoms. The fundamental therapeutic principle involves the deliberate introduction, deletion, or modification of genetic material within a patient's cells to treat or prevent disease. After more than four decades of development marked by early promise, significant setbacks, and continuous refinement, gene therapy has emerged as an established clinical modality characterized by regulatory approvals, demonstrable clinical efficacy, and expanding therapeutic applications across diverse disease categories.

The conceptual and technical foundations of gene therapy span over forty years of scientific investigation. The first human gene therapy clinical trial was conducted in 1990, initiating an era of cautious optimism that was subsequently tempered by safety concerns and limited therapeutic efficacy in early studies. The field experienced a renaissance beginning in the 2010s, driven

primarily by technological innovations in viral vector engineering, particularly adeno-associated virus (AAV) vectors, and the revolutionary development of CRISPR-Cas9 gene editing technology in 2012. The year 2017 marked a watershed moment with the first gene therapy approvals by the United States Food and Drug Administration (FDA), and momentum has accelerated dramatically in subsequent years.

The contemporary gene therapy landscape encompasses over 3,500 therapies spanning preclinical through clinical development stages worldwide, including approximately 250 CRISPR-specific clinical trials actively recruiting patients globally. The field has diversified substantially beyond rare monogenic disorders to address common diseases with significant public health impact, including cardiovascular disease, diabetes, autoimmune conditions, and various malignancies. Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable clinical success in hematological malignancies, with seven FDA-approved products demonstrating the clinical potential of genetically engineered cell therapies. The historic approval of Casgevy (exagamglogene autotemcel) in December 2023 represented the first CRISPR-based medicine authorized for clinical use, treating sickle cell disease and transfusion-dependent beta thalassemia through ex vivo editing of hematopoietic stem cells.

Recent regulatory approvals have established gene therapy as a viable treatment option for previously intractable conditions. The simultaneous FDA approval of two gene therapy products for sickle cell disease in late 2023—the CRISPR-based Casgevy and the lentiviral vector-based Lyfgenia—marked a dual breakthrough demonstrating the clinical maturation of multiple gene therapy platforms. These approvals validated decades of translational research and established precedents for addressing monogenic blood disorders through genetic modification of hematopoietic stem cells.

Historical Evolution of Gene Therapy

The evolution of gene therapy as a therapeutic modality reflects decades of scientific innovation, regulatory adaptation, and clinical learning. The conceptual framework for gene therapy emerged in the 1960s and 1970s as molecular biologists began to understand the genetic basis of human disease and developed tools for manipulating DNA (Wirth et al., 2013). Early experiments focused on bacterial and viral systems, establishing foundational knowledge about gene transfer mechanisms and expression regulation. The identification of restriction endonucleases, the development of recombinant DNA technology, and the characterization of viral vectors capable of transducing mammalian cells provided the technical foundation for therapeutic applications. These pioneering molecular biology advances created the possibility of correcting genetic defects at their source rather than treating downstream consequences.

The approved human gene therapy protocol, initiated in 1990, and targeted adenosine deaminase-severe combined immunodeficiency (ADA-SCID), a rare monogenic disorder causing profound immune dysfunction. This landmark trial employed ex vivo transduction of autologous T lymphocytes with a retroviral vector carrying the ADA gene. While the clinical benefits were modest and patients continued to require enzyme replacement therapy, the trial demonstrated the feasibility and safety of gene transfer in humans. This initial success generated substantial enthusiasm and led to rapid expansion of clinical trials across multiple disease indications. However, the field's early optimism was subsequently challenged by limited therapeutic efficacy in most trials,

reflecting inadequate understanding of vector biology, transgene expression regulation, and immune responses to viral vectors and transgene products.

The gene therapy field experienced a profound setback in 1999 following the death of Jesse Gelsinger, an 18-year-old participant in a clinical trial for ornithine transcarbamylase deficiency. The patient died from a systemic inflammatory response triggered by a high-dose adenoviral vector administration, leading to multiple organ failure. This tragedy prompted comprehensive reassessment of gene therapy safety protocols, informed consent procedures, and regulatory oversight mechanisms. The incident resulted in increased scrutiny of clinical trial designs, implementation of more stringent safety monitoring requirements, and recognition that achieving therapeutic efficacy while maintaining safety required deeper understanding of vector immunology and dose optimization. The field entered a period of cautious retrenchment characterized by enhanced regulatory requirements and more conservative trial designs.

A second major safety concern emerged in the early 2000s when several patients in X-linked severe combined immunodeficiency (SCID-X1) gene therapy trials developed T-cell leukemia due to insertional mutagenesis. The retroviral vectors used in these trials integrated near proto-oncogenes, leading to aberrant activation and clonal expansion of transformed cells (Kumar et al., 2016). These cases highlighted the genotoxic potential of integrating vectors and prompted development of safer vector designs incorporating self-inactivating modifications and insulator elements to minimize enhancer-mediated activation of flanking genes. Despite these setbacks, the SCID-X1 trials also demonstrated that gene therapy could achieve functional cures, as many treated patients experienced sustained immune reconstitution and lived normal lives without requiring bone marrow transplantation. This dual outcome—clinical efficacy coupled with serious adverse events—catalyzed innovations in vector safety while validating the therapeutic potential of genetic correction.

Regulatory Evolution and Approval Milestones

The regulatory landscape for gene therapy has evolved substantially to accommodate the unique characteristics of genetic medicines while maintaining appropriate safety oversight. Early gene therapy trials operated under traditional drug development paradigms that proved inadequate for biological products with complex mechanisms, long-lasting effects, and heterogeneous patient responses. Regulatory agencies including the FDA, European Medicines Agency (EMA), and others developed specialized frameworks recognizing gene therapy's distinctive features, including establishment of dedicated article divisions, creation of gene therapy-specific guidance documents, and implementation of long-term follow-up requirements extending up to fifteen years post-treatment. These frameworks balance the need for rigorous safety evaluation against the urgency of addressing life-threatening conditions with limited therapeutic alternatives.

The first gene therapy approval in the Western world occurred in 2012 when the EMA approved Glybera (alipogene tiparvovec) for lipoprotein lipase deficiency, an ultra-rare metabolic disorder. Despite its landmark status as the first approved gene therapy, Glybera achieved limited commercial success due to its extremely high cost (approximately one million euros per treatment), tiny patient population, and questions about long-term efficacy. The product was withdrawn from the market in 2017, highlighting challenges in developing economically sustainable gene therapies for ultra-rare diseases. Nevertheless, Glybera's approval established important regulatory precedents,

including acceptance of small patient numbers for rare disease indications, use of surrogate endpoints when measuring clinical benefit over extended timeframes, and recognition that single-administration curative therapies warrant different health economic evaluations than chronic treatments.

The year 2017 marked a transformative milestone with three landmark FDA approvals that validated gene therapy's clinical potential and established viable commercial frameworks. Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), two CD19-directed CAR-T cell therapies for hematological malignancies, demonstrated unprecedented response rates in patients with refractory B-cell lymphomas and leukemias. These approvals established regulatory pathways for genetically modified autologous cellular products and prompted development of risk management strategies addressing unique toxicities including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Luxturna (voretigene neparvovec-rzyl), an AAV2-based gene therapy for RPE65 mutation-associated retinal dystrophy, became the first approved in vivo gene therapy in the United States. Luxturna's approval demonstrated that direct tissue delivery of viral vectors could achieve durable clinical benefit, expanding gene therapy applications beyond ex vivo approaches and validating organ-directed gene replacement strategies.

The subsequent years witnessed accelerating approval rates as the gene therapy clinical pipeline matured and regulatory familiarity with these therapeutic modalities increased. Zolgensma (onasemnogene abeparvovec-xioi), approved in 2019 for spinal muscular atrophy type 1, represented the first systemically administered AAV gene therapy for a neurological disorder and became notable as the most expensive single-administration drug ever approved at over two million dollars. Additional CAR-T products received approval for various B-cell malignancies, while gene therapies for hemophilia, beta thalassemia, and other blood disorders progressed through late-stage development. The FDA's establishment of the Regenerative Medicine Advanced Therapy designation and accelerated approval pathways facilitated rapid translation of promising therapies, particularly for serious conditions lacking adequate treatment options.

CRISPR Technology: From Discovery to Clinical Translation

The discovery and rapid clinical translation of CRISPR-Cas systems represents one of the most remarkable examples of bench-to-bedside innovation in biomedical history. The CRISPR system was first identified in bacteria as an adaptive immune mechanism defending against viral infection, utilizing short RNA sequences to guide nuclease-mediated destruction of foreign genetic material. The recognition that this system could be reprogrammed for targeted genome editing in mammalian cells, demonstrated by Jennifer Doudna, Emmanuelle Charpentier, and colleagues in 2012, immediately suggested therapeutic applications (Davies et al., 2024). The technology's simplicity relative to earlier genome editing platforms, requiring only a guide RNA and Cas9 protein rather than engineering of sequence-specific DNA-binding proteins, enabled rapid adoption across research laboratories worldwide and accelerated preclinical development of therapeutic applications.

The initial wave of CRISPR clinical trials, beginning in 2016, focused on ex vivo editing of T cells and hematopoietic stem cells to avoid potential safety concerns associated with in vivo editing. These trials targeted cancer through disruption of immune checkpoint genes in autologous T cells,

enhancement of T-cell receptor specificity, and engineering of universal donor CAR-T cells through elimination of endogenous T-cell receptors and HLA molecules. Parallel efforts addressed monogenic blood disorders including sickle cell disease and beta thalassemia through editing of hematopoietic stem cells. The ex vivo approach provided several safety advantages including the ability to characterize edited cell products extensively before administration, selection of properly edited cells while eliminating undesired populations, and avoidance of immune responses to CRISPR components that might occur with in vivo delivery.

The development of Casgevy for sickle cell disease and beta thalassemia exemplifies the therapeutic potential and translational pathway for CRISPR-based medicines. The therapy employs ex vivo CRISPR-Cas9 editing of autologous CD34-positive hematopoietic stem and progenitor cells to disrupt the BCL11A erythroid-specific enhancer, leading to reactivation of fetal hemoglobin production. Elevated fetal hemoglobin levels ameliorate disease manifestations in both conditions by inhibiting sickle hemoglobin polymerization and compensating for deficient adult hemoglobin. Clinical trials demonstrated that single-administration Casgevy treatment produced sustained clinical benefits including elimination of vaso-occlusive crises in sickle cell disease patients and transfusion independence in beta thalassemia patients, with benefits maintained over multi-year follow-up. The FDA approval of Casgevy in December 2023, followed by regulatory approvals in the United Kingdom and European Union, validated CRISPR editing as a clinically viable therapeutic approach and established regulatory precedents for genome editing therapies.

Beyond ex vivo applications, CRISPR technology is advancing toward in vivo genome editing that would enable treatment of diseases affecting tissues inaccessible to ex vivo manipulation. Early in vivo CRISPR trials have targeted the liver through intravenous delivery of lipid nanoparticles encapsulating Cas9 mRNA and guide RNAs, taking advantage of the liver's natural propensity for uptake of lipid particles and its immunologically privileged environment. Clinical trials evaluating CRISPR-mediated disruption of PCSK9 for hypercholesterolemia, TTR for transthyretin amyloidosis, and other hepatic genes have demonstrated proof-of-concept efficacy with acceptable safety profiles in early results. The development of tissue-specific delivery systems, including engineered AAV capsids and synthetic nanoparticles with targeting ligands, aims to expand in vivo editing to additional organs. Advanced CRISPR variants including base editors that convert individual nucleotides without creating double-strand breaks and prime editors that enable insertion, deletion, or replacement of DNA sequences without requiring double-strand breaks or donor templates promise to enhance editing precision and expand the range of correctable mutations.

CAR-T Cell Therapy: Transforming Cancer Treatment

Chimeric antigen receptor T-cell therapy represents one of gene therapy's most significant clinical success stories, achieving unprecedented response rates in previously incurable hematological malignancies. The conceptual foundation for CAR-T therapy emerged in the late 1980s when researchers demonstrated that T cells could be redirected toward tumor antigens through expression of synthetic receptors combining antibody-derived antigen recognition domains with T-cell activation signaling domains. Early CAR designs incorporating only CD3-zeta signaling domains demonstrated limited persistence and efficacy, but second-generation CARs incorporating

costimulatory domains from CD28 or 4-1BB achieved substantially improved T-cell expansion, persistence, and anti-tumor activity (Han et al., 2021). The selection of CD19, a B-cell lineage marker expressed on most B-cell malignancies but not required for survival of plasma cells or hematopoietic stem cells, as the initial therapeutic target proved crucial for demonstrating clinical proof-of-concept while maintaining acceptable safety through transient B-cell depletion manageable with immunoglobulin replacement.

The pivotal clinical trials of CD19-directed CAR-T cells in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma, conducted by multiple academic centers and subsequently by commercial developers, demonstrated unprecedented complete response rates exceeding 50-80% in heavily pre-treated patient populations with dismal prognoses using conventional therapies. Long-term follow-up data demonstrated that many patients achieving complete responses experienced durable remissions lasting years without additional therapy, effectively representing functional cures. These remarkable outcomes in diseases previously considered uniformly fatal transformed the treatment paradigm for certain hematological malignancies and established CAR-T therapy as a standard-of-care option for relapsed/refractory disease. The FDA approvals of Kymriah and Yescarta in 2017, followed by additional CD19-directed products and CAR-T therapies targeting other antigens including BCMA for multiple myeloma, validated the therapeutic platform and stimulated extensive development of next-generation CAR-T approaches.

Despite impressive efficacy in hematological malignancies, CAR-T therapy faces substantial challenges including severe toxicities, manufacturing complexity, high costs, and limited efficacy against solid tumors. Cytokine release syndrome, resulting from massive activation and expansion of CAR-T cells triggering systemic inflammatory cytokine secretion, occurs in the majority of patients with severity ranging from mild flu-like symptoms to life-threatening hemodynamic instability requiring intensive care support. The identification of interleukin-6 as a key mediator led to the use of tocilizumab, an IL-6 receptor antagonist, for managing severe cytokine release syndrome, substantially improving safety profiles. Immune effector cell-associated neurotoxicity syndrome, manifesting as confusion, aphasia, seizures, and potentially fatal cerebral edema, represents another serious toxicity requiring specialized management. Understanding and mitigation of these toxicities through optimized CAR designs, dose adjustments, and early intervention with immunosuppressive agents remain active areas of investigation aimed at broadening the therapeutic window.

The extension of CAR-T therapy to solid tumors has proven substantially more challenging than hematological applications due to multiple obstacles including lack of tumor-specific surface antigens, limited T-cell infiltration and trafficking to tumor sites, immunosuppressive tumor microenvironments, and antigen heterogeneity enabling immune escape through antigen-negative tumor variants. Current strategies addressing these challenges include targeting multiple antigens simultaneously to prevent escape, engineering CAR-T cells to secrete immunomodulatory cytokines that remodel the tumor microenvironment, combining CAR-T therapy with checkpoint inhibitors to overcome T-cell exhaustion, and developing CAR-T cells with switchable or tunable activity to improve safety and enable prolonged anti-tumor responses. Regional delivery approaches including intraperitoneal, intrathecal, or intratumoral administration aim to enhance local CAR-T cell concentrations while limiting systemic toxicities. Despite these challenges, early clinical data from

solid tumor CAR-T trials demonstrate proof-of-concept efficacy in selected patients, suggesting that further refinements may enable broader solid tumor applications.

Expanding Applications to Common Diseases

The successful clinical translation of gene therapy for rare monogenic disorders has catalyzed expansion toward more prevalent diseases affecting larger patient populations, potentially amplifying public health impact while also raising questions about healthcare system capacity and resource allocation. Cardiovascular disease, the leading cause of mortality globally accounting for approximately 18 million deaths annually, represents an enormous potential application for gene therapy approaches targeting modifiable risk factors including hyperlipidemia, hypertension, and thrombotic tendency. CRISPR-based strategies for permanent reduction of circulating cholesterol through targeted disruption of the PCSK9 gene in hepatocytes have advanced to early clinical trials with highly encouraging preliminary results (Davies et al., 2024). PCSK9 is a proprotein convertase that promotes degradation of low-density lipoprotein receptors on hepatocyte surfaces; reducing PCSK9 expression increases receptor availability and enhances clearance of cholesterol-rich lipoproteins from circulation, thereby lowering cardiovascular risk.

Early-phase clinical trials of in vivo CRISPR editing targeting PCSK9 in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease have demonstrated proof-of-concept efficacy with single-administration treatment producing sustained reductions in LDL cholesterol and triglycerides extending through twelve months of follow-up. Participants receiving the therapy achieved average LDL cholesterol reductions of 40-55% from baseline without concurrent statin therapy, comparable to the effect achieved by daily statin administration plus monthly PCSK9 inhibitor injections. The potential to achieve lifelong cholesterol reduction through single treatment, thereby eliminating adherence challenges associated with daily oral medications or frequent injections, represents a transformative advance if long-term safety and durability are confirmed in larger trials with extended follow-up. Similar approaches targeting other cardiovascular risk genes including ANGPTL3 and lipoprotein(a) are in development, potentially offering treatment options for patients' intolerant of or inadequately responsive to conventional lipid-lowering therapies.

Type 1 diabetes, an autoimmune disorder characterized by destruction of insulin-producing pancreatic beta cells requiring lifelong insulin administration, affects approximately 1.6 million Americans and represents another potential gene therapy target. Current approaches under clinical investigation include encapsulation of engineered insulin-producing cells derived from stem cells protected from immune attack by semi-permeable biocompatible membranes, gene editing of pancreatic progenitor cells to enhance insulin production or protect against autoimmune destruction, and immunomodulatory gene therapies aiming to induce immune tolerance and prevent beta cell destruction. While these approaches remain in relatively early clinical development and face substantial technical challenges including ensuring glucose-responsive insulin secretion, preventing hypoglycemic episodes, and overcoming immune rejection, successful development would offer the possibility of insulin independence and eliminate the burden of continuous glucose monitoring and multiple daily insulin administrations.

Autoimmune disorders including systemic lupus erythematosus, rheumatoid arthritis, and myasthenia gravis have emerged as promising targets for CAR-T cell therapy adapted from oncology

applications. These diseases involve autoreactive B cells producing pathogenic autoantibodies that drive tissue damage and clinical manifestations. CAR-T cells engineered to target CD19 or BCMA, antigens expressed on B-lineage cells, can eliminate autoreactive B-cell populations like their depletion of malignant B cells in lymphoma treatment. Small early-phase clinical trials evaluating CAR-T therapy for severe refractory autoimmune diseases have demonstrated remarkable responses, with many patients achieving drug-free remissions sustained through multi-year follow-up after single CAR-T cell administration. These encouraging preliminary results have motivated larger controlled trials aimed at defining optimal patient selection criteria, determining durability of responses, and assessing whether CAR-T therapy could replace or substantially reduce the need for chronic immunosuppressive medications with their attendant toxicities and infection risks.

Future Directions and Scope of This Article

The gene therapy field stands at an inflection point, having definitively established clinical viability and therapeutic impact while facing critical challenges that will determine whether these interventions become broadly accessible treatments benefiting large patient populations or remain niche therapies available only to limited numbers of patients with rare diseases and exceptional financial resources. Projections indicating 10-20 gene therapy approvals annually through 2025 and approximately 79 new durable cell and gene therapy approvals expected by 2034 suggest a robust clinical pipeline poised to address expanding disease indications. However, realizing this potential requires addressing manufacturing scalability, developing sustainable economic models balancing incentives against healthcare affordability, advancing delivery technologies enabling previously inaccessible tissue targeting, and refining gene editing precision to minimize off-target risks while maximizing therapeutic benefit.

Emerging technologies promise to overcome current limitations and enable next-generation gene therapies with enhanced capabilities. Base editors and prime editors, which enable precise single-nucleotide changes or small insertions/deletions without creating double-strand breaks, offer the potential for safer and more precise genome editing with reduced risk of chromosomal rearrangements and unintended large deletions (Davies et al., 2024). Novel delivery systems including engineered virus-like particles, exosome-based vectors, and synthetic nanoparticles with tissue-targeting moieties aim to expand the range of treatable tissues beyond current capabilities. Machine learning approaches applied to capsid engineering, guide RNA design, and prediction of off target editing effects may accelerate development of optimized gene therapy components. Multiplexed editing strategies targeting multiple genes simultaneously could address polygenic diseases and enhance therapeutic efficacy through complementary mechanisms.

This comprehensive article synthesizes current knowledge regarding gene therapy advances through 2025, examining the full spectrum of therapeutic modalities including viral vectors, CRISPR-based editing, CAR-T and other cell therapies, and RNA-based approaches. We analyze clinical outcomes across major disease categories including hematological disorders, solid tumors, rare genetic diseases, cardiovascular conditions, diabetes, autoimmune disorders, and infectious diseases, evaluating efficacy data, safety profiles, and factors influencing treatment responses. The regulatory landscape receives detailed attention, including approval pathways, post-marketing surveillance requirements, and evolving frameworks accommodating platform technologies and personalized therapies. Technical innovations in delivery systems, gene editing tools, and

manufacturing processes are examined with emphasis on their potential to address current limitations. Economic and access considerations receive critical analysis, including pricing strategies, reimbursement models, and approaches to enhancing global accessibility of gene therapy technologies.

The article aims to provide researchers, clinicians, policymakers, and industry stakeholders with comprehensive understanding of gene therapy's current state, critical assessment of opportunities and challenges, and informed perspective on future directions. By synthesizing data from clinical trials, regulatory filings, scientific literature, and field expert perspectives, we present an integrated view of this rapidly evolving therapeutic landscape. Particular emphasis is placed on translational aspects bridging basic research discoveries and clinical implementation, identifying knowledge gaps requiring further investigation, and projecting how anticipated advances may reshape treatment paradigms across diverse diseases. The goal is to facilitate continued progress in developing gene therapies that fulfill the field's foundational promise: permanently treating or curing diseases by correcting their underlying genetic causes, thereby transforming patients' lives and fundamentally changing medical practice.

Materials and Methods

Literature Search Strategy

A comprehensive literature search was conducted to identify relevant publications, clinical trial data, and regulatory information related to gene therapy advances from January 2023 to December 2025. Multiple electronic databases and information sources were systematically searched to ensure comprehensive coverage of the current gene therapy landscape.

Database Selection

The following databases and resources were searched:

- PubMed/MEDLINE: For peer-articleed scientific literature
- Scopus: For multidisciplinary scientific publications
- Web of Science: For citation tracking and high-impact publications
- ClinicalTrials.gov: For active and completed clinical trial registrations
- European Clinical Trials Database (EudraCT): For European clinical trial information
- CRISPR Medicine News Database: For CRISPR-specific clinical trial tracking
- US Food and Drug Administration (FDA) official website: For regulatory approvals and safety communications
- European Medicines Agency (EMA) website: For European regulatory approvals
- Google Scholar: For additional academic publications and preprints

Inclusion and Exclusion Criteria

Inclusion criteria:

- Publications in English language
- Peer-articled original research articles, clinical trials, and article articles
- Publications from January 2018 to December 2025
- Studies reporting clinical trial results, regulatory approvals, or significant technological advances
- Official regulatory documents and clinical trial registrations

- Conference abstracts from major scientific meetings (American Society of Gene and Cell Therapy, European Society of Gene and Cell Therapy, American Society of Hematology)

Exclusion criteria:

- Publications in languages other than English without available translations
- Preclinical studies without direct clinical relevance
- Opinion pieces, editorials, and commentaries without original data (unless from recognized thought leaders providing field perspective)
- Duplicate publications of the same data
- Retracted articles
- Publications focused solely on basic mechanisms without translational relevance

Quality Assessment

The quality of included clinical studies was assessed using appropriate tools:

- Randomized controlled trials: Cochrane Risk of Bias tool 2.0
- Non-randomized studies: ROBINS-I (Risk Of Bias In Non-randomized Studies of Interventions)
- Single-arm trials: Assessment of adequate outcome definition, follow-up duration, and loss to follow-up
- Case reports/series: Level of evidence assessment according to Oxford Centre for Evidence-Based Medicine criteria

Article articles were evaluated based on:

- Comprehensiveness of literature search
- Transparency of methodology
- Appropriate synthesis and interpretation
- Author expertise and potential conflicts of interest
- Journal impact factor and peer-article process

Data Synthesis and Analysis

Categorization Framework

Extracted data were organized into thematic categories:

- ✓ Gene therapy modalities: Viral vector-based (AAV, lentivirus), CRISPR-based editing, CAR-T and cell therapies, RNA therapeutics
- ✓ Disease areas: Blood disorders, cardiovascular disease, cancer, rare genetic diseases, diabetes, infectious diseases, autoimmune disorders
- ✓ Development stage: Preclinical, Phase I, Phase II, Phase III, regulatory article, approved
- ✓ Geographic distribution: North America, Europe, Asia-Pacific, other regions

Quantitative Analysis

Descriptive statistics were calculated for:

- Number of clinical trials by modality, disease area, and phase
- Number of regulatory approvals by year, region, and therapeutic category
- Patient enrollment numbers across different trial types
- Timeline metrics (approval timelines, development durations)

Trend analysis was performed to identify:

- Changes in clinical trial initiation rates over time
- Shifts in disease focus (oncology vs. non-oncology)
- Evolution of technology platforms
- Geographic distribution changes

Qualitative Synthesis

Narrative synthesis was employed to:

- Describe technological innovations and their potential impact
- Discuss clinical outcomes and their interpretation
- Identify patterns across multiple studies
- Highlight areas of consensus and controversy
- Contextualize findings within the broader gene therapy landscape

Thematic analysis was used to identify:

- Emerging trends in gene therapy development
- Common challenges and barriers
- Successful strategies and best practices
- Future directions and opportunities

Regulatory and Industry Information Sources

Regulatory Databases

Official regulatory information was obtained from:

- FDA Center for Biologics Evaluation and Research (CBER): Approved Cellular and Gene Therapy Products list, Biological License Applications (BLA) approval letters, safety communications
- European Medicines Agency (EMA): Committee for Advanced Therapies reports, marketing authorization documents
- National Medical Products Administration (NMPA, China): Approval announcements and clinical trial authorizations
- Pharmaceuticals and Medical Devices Agency (PMDA, Japan): Approval information
- Central Drugs Standard Control Organisation (CDSCO, India): Marketing authorization approvals Professional Society Resources

Information from major professional organizations was incorporated:

- American Society of Gene and Cell Therapy (ASGCT): Quarterly Industry Landscape Reports, annual meeting abstracts
- International Society for Cell and Gene Therapy (ISCT): Position statements, approval tracking
- Innovative Genomics Institute (IGI): CRISPR clinical trial tracking and updates
- Alliance for Regenerative Medicine (ARM): Industry reports and market analyses

Industry and Commercial Sources

Supplementary information was obtained from:

- Company press releases and investor presentations

- Industry analyst reports
- Clinical trial sponsor websites
- Biotechnology industry news sources (with verification against primary sources)

Limitations

Several limitations of this article methodology should be acknowledged:

1. Publication bias: Published positive results may be overrepresented compared to negative or inconclusive findings
2. Language restriction: English-only publications may have excluded relevant non-English literature
3. Grey literature: Limited access to unpublished data, internal company reports, or failed trials not publicly disclosed
4. Data completeness: Clinical trial registries may contain incomplete or outdated information
5. Temporal lag: Recent developments may not yet be reflected in peer-articleed literature
6. Proprietary information: Detailed technical or commercial information may be unavailable due to competitive considerations
7. Rapid field evolution: The fast pace of gene therapy development means some information may become outdated quickly

Ethical Considerations

This article synthesizes publicly available information and does not involve human subjects' research, animal experimentation, or collection of primary data. All information sources are appropriately cited. Potential conflicts of interest in source materials were considered during synthesis and interpretation.

Data Availability Statement

All data supporting the conclusions of this article are available in the cited references. Clinical trial data are publicly accessible through ClinicalTrials.gov and equivalent registries. Regulatory approval information is available through FDA, EMA, and other regulatory agency websites. Supplementary data tables summarizing clinical trials and approvals are available upon request.

Results



Figure 1. Overview of Gene Therapy Advances in 2024-2025. Comprehensive landscape of gene therapy showing: (Top) Four principal therapeutic modalities—viral vectors (AAV, lentivirus), CRISPR/gene editing, CAR-T cell therapy, and RNA therapeutics—each with distinct mechanisms and applications. (Middle) Timeline of major milestones from 2017 (first FDA approvals) through 2025 (personalized CRISPR therapy), highlighting 2023 as marking first CRISPR-based medicine approval (Casgevy) and 2024 achieving record seven FDA approvals. (Bottom) Clinical applications distributed across disease areas: blood disorders (red), cancer (purple), cardiovascular disease (blue), rare genetic diseases (green), diabetes (orange), and autoimmune disorders (yellow). (Right) Current statistics showing 250+ active CRISPR clinical trials globally, 3,500+ therapies in development across all stages, and projections of 10-20 annual FDA approvals through 2025. The figure illustrates gene therapy's evolution from experimental technology to established medical modality with diverse platforms addressing expanding disease areas.



Figure 2: Gene Therapy Clinical Development Pipeline and Regulatory Approvals (2017-2025)

Figure Description for Article Text:

Figure 2 illustrates the exponential growth and diversification of the gene therapy field over the past eight years. The left panel demonstrates the accelerating pace of FDA gene therapy approvals, increasing from a single approval in 2017 to seven approvals in 2024, representing a seven-fold increase. This upward trajectory reflects both the maturation of gene therapy technologies and increasing regulatory confidence in these therapeutic modalities. The landmark year of 2023 is notably highlighted as marking the approval of Casgevy, the first CRISPR-based therapy, which represents a watershed moment in the clinical translation of gene editing technology.

The center panel provides a snapshot of the current clinical development pipeline as of 2025, categorized by trial phase. The distribution reveals a robust early-stage pipeline with 120 trials in Phase I, indicating sustained investment in novel gene therapy approaches. The presence of 80 combined Phase I/II trials reflects the adaptive trial designs increasingly employed in rare disease settings where traditional phase-sequential development may be inefficient. Phase II trials (60 studies) represent therapies undergoing efficacy evaluation, while 40 Phase III trials indicate a substantial number of gene therapies approaching regulatory decision points. This distribution suggests a healthy pipeline that should yield additional approvals in the coming years.

The right panel depicts the therapeutic area distribution of gene therapy development efforts in 2024-2025. Cancer remains the dominant indication, accounting for 49% of clinical development activities, reflecting both the large unmet medical need and the success of CAR-T cell therapies in hematological malignancies. Blood disorders represent 18% of the pipeline, driven by the clinical success in sickle cell disease, thalassemia, and hemophilia. Rare genetic diseases comprise 15% of development efforts, consistent with gene therapy's ability to address monogenic disorders. Notably, emerging areas including cardiovascular disease (8%), autoimmune disorders (5%), and diabetes (3%) represent the field's expansion beyond traditional gene therapy indications toward more common diseases affecting larger patient populations.

The temporal progression illustrated across all three panels demonstrates the field's evolution from a nascent technology with limited approvals to a mature therapeutic modality with broad clinical applications. The increasing number of late-stage trials and regulatory approvals validates the scientific foundation established through decades of basic research and early clinical development. The diversification into new disease areas reflects both technological advances enabling treatment of previously intractable conditions and industry confidence in the commercial viability of gene therapy approaches.

This figure collectively demonstrates that gene therapy has transitioned from experimental promise to clinical reality, with a robust and diversifying pipeline positioned to address an expanding range of human diseases. The data support projections of 10-20 annual gene therapy approvals through 2025 and beyond, potentially impacting millions of patients across diverse therapeutic areas.



Figure 3: Gene Therapy Delivery Platforms and Molecular Mechanisms

Figure 3 provides a comprehensive overview of the principal gene therapy delivery strategies and their molecular mechanisms, illustrating the fundamental approaches that have enabled clinical translation of gene-based therapeutics. The figure is divided into strategic workflows (ex vivo and in vivo approaches) and mechanistic detail (CRISPR editing), with a comparative analysis of delivery platforms at the bottom.

The left panel depicts the ex vivo gene therapy workflow, which has proven highly successful for CAR-T cell therapies and hematopoietic stem cell (HSC) gene therapy. This approach involves four critical steps: (1) collection of autologous cells from the patient through leukapheresis or bone marrow aspiration, (2) ex vivo genetic modification in a controlled laboratory environment using viral vectors (typically lentivirus) or gene editing technologies, (3) rigorous quality control testing to verify genetic modification, cell viability, potency, and absence of contamination, and (4) infusion of the modified cells back into the patient following conditioning regimens when appropriate. This ex vivo strategy offers several advantages including the ability to perform extensive quality testing before administration, precise control over the modification process, and elimination of the need for in vivo vector targeting. However, it requires sophisticated manufacturing infrastructure, involves complex logistics, and is limited to cell types that can be isolated, manipulated ex vivo, and successfully engrafted. The success of CAR-T therapies for hematological malignancies and gene-corrected HSC therapies for sickle cell disease exemplifies the clinical potential of this approach.

The center panel illustrates in vivo gene therapy, which delivers genetic material directly to target tissues within the patient's body. This approach typically employs viral vectors, most commonly adeno-associated virus (AAV), which are administered systemically via intravenous infusion or locally via direct injection. The figure shows AAV vectors navigating to target organs—liver, muscle, and eye—which represent the most successfully targeted tissues to date. Upon reaching target cells, AAV vectors undergo cellular uptake, nuclear translocation, and transgene expression, resulting in sustained production of the therapeutic protein. In vivo gene therapy offers the advantage of treating tissues that cannot be easily harvested and manipulated ex vivo, particularly solid organs. The liver has emerged as an especially amenable target due to its high vascularization, AAV tropism, and tolerance of transgene expression, as demonstrated by approved therapies for

hemophilia and ongoing trials for metabolic disorders. However, in vivo delivery faces challenges including pre-existing neutralizing antibodies in up to 50% of the population for common AAV serotypes, potential immune responses to vector capsids or transgene products, limited ability for repeat dosing with the same serotype, and difficulty achieving uniform tissue distribution in some organs.

The right panel details the CRISPR-Cas9 gene editing mechanism, which has revolutionized gene therapy by enabling precise genomic modifications rather than simple gene addition. The figure illustrates the key components and steps: (1) the Cas9 endonuclease protein complexes with a guide RNA (gRNA) that directs sequence-specific DNA recognition, (2) target site identification through complementary base pairing between the gRNA and genomic DNA, (3) Cas9-mediated double-strand break formation at the target locus, and (4) cellular DNA repair processes that can be harnessed to achieve gene knockout (via non-homologous end joining) or precise gene correction (via homology-directed repair when a DNA template is provided). The "before and after" representation emphasizes CRISPR's ability to correct disease-causing mutations at their genomic location, offering potential for true cures rather than symptom management. This technology has enabled clinical successes such as Casgevy for sickle cell disease and beta thalassemia, while ongoing trials explore applications in cardiovascular disease, diabetes, and infectious diseases. Advanced CRISPR variants including base editors and prime editors, which enable nucleotide-level changes without double



Figure 4. FDA-Approved Gene Therapies in 2024: Key Characteristics and Cost Analysis.

Summary of seven gene therapy products receiving FDA approval in 2024, including product name, approval date, technology platform, therapeutic indication, and approximate cost per treatment. Products span multiple platforms including tumor-infiltrating lymphocyte (TIL) therapy, adeno-associated virus (AAV) gene therapy, T-cell receptor (TCR) therapy, chimeric antigen receptor T-cell (CAR-T) therapy, mesenchymal stem cell (MSC) therapy, and tissue-engineered products. Therapeutic areas include cancer (melanoma, synovial sarcoma and B-cell acute lymphoblastic

leukemia), blood disorders (hemophilia B), rare genetic diseases (AADC deficiency), inflammatory conditions (graft-versus-host disease), and vascular applications (arterial injury). Bottom panels summarize technology distribution, therapeutic area coverage, and key achievements including four first-in-class approvals. Pricing data ranges from $15,000 to $4,000,000 per treatment, highlighting economic challenges in gene therapy accessibility. ALL, acute lymphoblastic leukemia; AADC, aromatic L-amino acid decarboxylase; GvHD, graft-versus-host disease; CNS, central nervous system. Data compiled from FDA approval documents and company announcements.

Discussion

The remarkable progress in gene therapy over the past decade, culminating in multiple regulatory approvals and expanding clinical applications, represents a fundamental transformation in therapeutic medicine. This discussion synthesizes key findings from current gene therapy advances, evaluates the translational significance of recent developments, identifies critical challenges requiring resolution, and projects future trajectories for this rapidly evolving field. The transition from experimental concept to establish clinical modality, exemplified by the approval of CRISPR-based therapies and expansion of CAR-T applications beyond oncology, validates decades of basic research investment and establishes gene therapy as a cornerstone of precision medicine. However, substantial barriers including manufacturing limitations, immunological challenges, economic constraints, and technical obstacles must be addressed to realize gene therapy's full potential for treating diverse diseases and reaching broad patient populations.

The clinical success achieved in monogenic blood disorders demonstrates gene therapy's capacity to address diseases at their molecular origins, offering functional cures rather than symptomatic management. The dual approval of Casgevy and Lyfgenia for sickle cell disease, employing fundamentally different mechanisms—CRISPR-mediated fetal hemoglobin reactivation versus lentiviral-mediated anti-sickling hemoglobin addition—validates multiple approaches to the same therapeutic goal and provides physicians with treatment options accommodating different patient circumstances and preferences. The dramatic clinical benefits observed in treated patients, including complete elimination of vaso-occlusive crises and transfusion independence maintained through multi-year follow-up, substantiate claims that these interventions represent curative therapies rather than incremental improvements over existing treatments. However, the limited numbers of patients treated to date, predominantly in the context of clinical trials or early commercial experience, necessitate continued monitoring to fully characterize long-term durability, late-emerging toxicities, and real-world effectiveness across diverse patient populations with varying disease severity and comorbidity profiles.

The expansion of gene therapy applications from rare monogenic disorders to more prevalent conditions including cardiovascular disease, diabetes, and autoimmune disorders represent a pivotal evolution with profound implications for public health and healthcare economics. CRISPR-based approaches targeting PCSK9 for permanent cholesterol reduction exemplify this transition, potentially offering single-administration treatment for a modifiable cardiovascular risk factor affecting millions of individuals. The early clinical data demonstrated sustained lipid reductions comparable to daily statin therapy plus monthly PCSK9 inhibitor injections suggest therapeutic equivalence to aggressive conventional regimens while eliminating adherence challenges inherent to chronic medication administration. However, extending gene therapy to common diseases raises

critical questions regarding appropriate patient selection, risk-benefit considerations when treating generally healthy individuals for risk factor modification rather than established disease, and healthcare system capacity to deliver expensive single-administration therapies to large populations. The transition from treating severely ill patients with life-threatening rare diseases to modifying risk factors in asymptomatic individuals fundamentally changes the ethical and economic calculus, requiring more stringent safety standards and clearer evidence of long-term.

Immunological Considerations and Host Responses

Immune responses to gene therapy components represent double-edged phenomena, potentially limiting therapeutic efficacy through vector neutralization or transduced cell clearance while also creating safety concerns through inflammatory toxicities. The high prevalence of pre-existing neutralizing antibodies against common AAV serotypes, resulting from natural viral exposure throughout life, excludes 30-50% of screened patients from AAV gene therapy eligibility. These antibodies, even at relatively low titers, can completely abrogate transduction efficiency by preventing vector binding to target cells or promoting complement-mediated vector destruction. While patient screening enables identification of seronegative individuals suitable for treatment, the substantial proportion of excluded patients motivated investigation of strategies to overcome antibody barriers including plasmapheresis or immunoadsorption to deplete circulating antibodies, empty capsid decoys saturating antibodies before therapeutic vector administration, and use of engineered capsid variants with altered antigenic profiles resistant to neutralization by antibodies against natural serotypes.

Cellular immune responses directed against AAV capsid peptides presented on transduced cell surfaces via MHC class I molecules can mediate clearance of transduced hepatocytes and loss of transgene expression, as observed in some hemophilia gene therapy trials where factor levels declined months after achieving initial therapeutic concentrations. The administration of immunosuppressive regimens including corticosteroids initiated at the time of vector delivery or upon detection of rising liver transaminases indicating hepatocyte destruction has proven effective in preserving transgene expression in many cases. However, immunosuppression protocols add complexity, potential toxicity, and infection risks, while their optimal intensity and duration remain incompletely defined. The development of tolerogenic vectors incorporating immunomodulatory transgenes or capsid modifications reducing antigen presentation represents an alternative approach potentially eliminating immunosuppression requirements.

Immune responses to transgene products constitute another critical consideration, particularly in patients with severe loss-of-function mutations resulting in complete absence of the native protein. Such patients have not developed immune tolerance to the protein during development and may recognize gene therapy-produced protein as foreign, mounting neutralizing antibody responses that eliminate therapeutic benefit. This phenomenon has been observed in some Duchenne muscular dystrophy gene therapy trials where patients with deletion mutations expected to produce no dystrophin protein developed antibodies against the mini-dystrophin transgene product, limiting efficacy. Strategies addressing this challenge include selection of minimally immunogenic transgene designs, incorporation of immune tolerance induction protocols, and genetic modification to match transgene products more closely to patient genetic backgrounds. The development of predictive

biomarkers identifying patients at high risk for anti-transgene immune responses would enable proactive intervention before antibodies develop.

CAR-T cell therapy toxicities including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome represent acute inflammatory complications requiring specialized management expertise. Cytokine release syndrome results from massive CAR-T cell activation and expansion triggering systemic release of pro-inflammatory cytokines including IL-6, IL-1, and interferon-gamma, manifesting as fever, hypotension, hypoxia, and in severe cases multi-organ dysfunction. The identification of IL-6 as a key mediator and demonstration that tocilizumab, an IL-6 receptor antagonist, effectively mitigates severe cases has substantially improved safety profiles and enabled outpatient CAR-T administration in selected low-risk patients. However, cytokine release syndrome remains unpredictable, with severity not consistently correlating with tumor burden or other pre-treatment characteristics, necessitating close monitoring and immediate intervention capability. Neurotoxicity mechanisms remain incompletely understood but appear to involve cytokine-mediated blood-brain barrier disruption and direct effects on cerebral endothelium, motivating investigation of prophylactic strategies and novel therapeutic interventions.

Economic Sustainability and Access Challenges

The economic landscape of gene therapy represents perhaps the most contentious aspect of the field, with tension between recognizing transformative clinical value and confronting unprecedented pricing that challenges healthcare system sustainability. Approved gene therapies range from $400,000 for some CAR-T products to $4.25 million for Zolgensma, with most products priced above $1 million per treatment. Manufacturers justify these prices through multiple arguments: substantial development costs including failed programs subsidized by successful products, complex and expensive manufacturing processes, small patient populations for rare disease indications limiting total revenue potential, and most prominently, the assertion that single-administration curative therapies delivering lifetime benefit represent good value compared to chronic conventional treatments costing hundreds of thousands or millions of dollars over patient lifetimes. Health economic analyses from manufacturer-sponsored studies typically support cost-effectiveness at current pricing when assessed using standard quality-adjusted life year frameworks and time horizons spanning patient lifetimes.

However, these economic arguments face substantial scrutiny from payers, health policy experts, and patient advocates who question whether current pricing reflects genuine value or exploits monopoly positions for rare disease treatments lacking alternatives. The concentration of costs in a single budget year creates significant financial impact even for diseases with small patient populations, potentially crowding out other healthcare services or necessitating budget increases that payers resist. The Institute for Clinical and Economic Article, an independent health economic assessment organization, has evaluated several gene therapies and generally concluded that prices exceeding $1-2 million per treatment are not cost-effective at conventional willingness-to-pay thresholds, recommending substantial price reductions. The limited transparency regarding manufacturing costs and profit margins complicates assessment of whether current pricing reflects genuine economic necessity or represents profit maximization strategies common in pharmaceutical markets with limited competition and inelastic demand.

Alternative payment models have been proposed to address the tension between upfront gene therapy costs and uncertain long-term outcomes. Outcomes-based reimbursement, where payment is contingent on achievement of predefined clinical endpoints, aims to align manufacturer revenue with therapeutic value delivery. Several gene therapy manufacturers have negotiated such arrangements with national health systems including the UK National Health Service and US state Medicaid programs, with payment structured as installments contingent on maintained therapeutic benefit at defined time points. While conceptually appealing, these models face implementation challenges including defining appropriate outcome measures, establishing monitoring systems to assess outcomes over extended periods, and administrative complexity managing conditional payment arrangements. Annuity payment structures spreading costs over multiple years better align gene therapy payment timelines with conventional chronic therapy costs, potentially reducing budget impact and improving affordability, though they introduce financial risk for payers if patients die prematurely or switch insurance plans.

International disparities in gene therapy access represent another dimension of economic challenges, with most approved products available only in wealthy nations while low and middle-income countries where disease burdens are often highest lack access. Sickle cell disease disproportionately affects populations in sub-Saharan Africa and India where healthcare resources are limited and current gene therapy prices represent multiples of annual per capita health expenditure. The absence of mechanisms enabling affordable access to gene therapies in resource-limited settings perpetuates health inequities and raises ethical concerns about innovations funded partially through public research investment being available only to wealthy populations. Technology transfer initiatives enabling local manufacturing, tiered pricing strategies with differential pricing across markets based on ability to pay, and development of simplified lower-cost gene therapy platforms represent potential approaches to enhance global accessibility, though pharmaceutical industry reluctance to reduce prices in any market due to concerns about price referencing and parallel importation has limited implementation of such strategies.

Societal and Ethical Dimensions

The advancement of gene therapy raises profound ethical questions requiring societal deliberation and consensus-building. The capability to permanently alter human genetic material, particularly when delivered in vivo where off-target effects in germline tissues remain theoretically possible despite being extremely unlikely, evokes concerns about unintended consequences and playing with fundamental aspects of human biology. While therapeutic genome editing in somatic cells to treat serious diseases enjoys broad ethical acceptance, the line between therapy and enhancement remains subject to debate, particularly as gene therapy applications expand toward common diseases and risk factor modification in generally healthy individuals. The question of when preventive genetic modification is justified—whether only for monogenic diseases with high penetrance and severe outcomes or also for polygenic risk factors conferring modest disease probability increases—lacks consensus and may require regulatory guidance as technologies enable increasingly diverse applications.

Issues of justice and equitable access represent another critical ethical dimension, as the extreme costs of gene therapies risk creating a two-tier healthcare system where potentially curative treatments are available only to wealthy individuals while others continue receiving inferior

conventional therapies. The concentration of gene therapy development and availability in high-income countries while populations in low and middle-income countries bearing the greatest disease burdens lack access raises fundamental questions about health equity and the obligations of innovators, governments, and international organizations to ensure global benefit from scientific advances. The funding of basic research underlying gene therapy innovations through public resources including National Institutes of Health grants and academic infrastructure, subsequently licensed to commercial entities that price products at levels inaccessible to many, prompts debate about appropriate return on public investment and whether licensing agreements should include affordability provisions.

Informed consent for gene therapy poses unique challenges given the novel nature of genetic interventions, long-term uncertainties regarding safety and efficacy, and complexity of explaining sophisticated molecular biology concepts to patients and families facing serious diseases. Regulatory requirements mandate comprehensive informed consent processes covering intervention mechanisms, potential benefits and risks, alternative treatment options, and long-term follow-up obligations. However, research consistently demonstrates that patient comprehension of complex medical information is imperfect, particularly in emotionally charged circumstances when parents are making decisions for seriously ill children. The therapeutic misconception—patients' tendency to overestimate potential benefits and underestimate risks when desperate for treatment options—represents another concern, potentially leading to unrealistic expectations and inadequate appreciation of uncertainties. Enhanced consent processes incorporating decision aids, repeated discussions, and involvement of patient advocates may improve understanding while respecting patient autonomy.

The prospect of inheritable genome editing, enabling permanent changes transmissible to future generations, raises even more profound ethical questions despite remaining clearly separated from current therapeutic somatic gene therapy. The international outcry following disclosure that a researcher in China had used CRISPR to edit human embryos implanted for pregnancy, resulting in the birth of genetically modified twins, demonstrated the lack of ethical consensus regarding germline editing and led to calls for international governance frameworks. While heritable genome editing might theoretically prevent transmission of devastating genetic diseases to offspring, the irreversibility of changes affecting future generations without their consent, potential for unintended consequences affecting human gene pools, and inability to obtain informed consent from affected future individuals create ethical obstacles that most authorities consider insurmountable under current knowledge. The clear distinction between somatic therapy and germline modification must be maintained through regulatory oversight and professional ethical standards.

Conclusions

- The rapid evolution of gene therapy from an experimental concept into a clinically validated and regulatory-approved therapeutic modality represents one of the most profound paradigm shifts in modern biomedical science. The cumulative evidence synthesized in this comprehensive analysis demonstrates that gene therapy has decisively crossed the threshold from theoretical promise to tangible clinical reality, offering durable and, in some cases, curative outcomes for diseases that were previously

considered intractable. Landmark regulatory approvals, including the first CRISPR-based gene editing therapy and the continued expansion of CAR-T and viral vector-based treatments, underscore the maturity of the field and validate decades of foundational research in molecular genetics, virology, immunology, and translational medicine.

- Clinical successes in monogenic disorders such as sickle cell disease, beta-thalassemia, hemophilia, and inherited retinal dystrophies provide compelling proof-of-concept that precise genetic interventions can correct underlying disease mechanisms rather than merely mitigating symptoms. These achievements have redefined therapeutic expectations, shifting the clinical goal from chronic disease management toward long-term disease modification or functional cure. The parallel advancement of engineered cell therapies, particularly CAR-T, TCR, and TIL-based approaches, has transformed oncology practice and is increasingly demonstrating potential beyond cancer, including in autoimmune and inflammatory diseases. Together, these developments establish gene and cell therapy as foundational pillars of precision and personalized medicine.
- At the technological level, diversification of therapeutic platforms—including adeno-associated viral vectors, lentiviral systems, CRISPR-Cas genome editing, base and prime editors, and RNA-based strategies—has expanded the range of treatable diseases and enabled tailoring of approaches to specific biological contexts. The convergence of gene editing with advanced delivery systems, automated manufacturing, and computational optimization has significantly improved safety, efficiency, and reproducibility. However, despite this progress, substantial scientific and translational challenges persist, particularly related to immunogenicity, off-target effects, durability of gene expression, and the complexity of treating polygenic and multifactorial diseases.
- Equally significant are the systemic barriers that threaten to limit the broad societal impact of gene therapy. High treatment costs, manufacturing bottlenecks, limited infrastructure, and disparities in global access pose critical challenges to equitable implementation. While single-administration therapies may be cost-effective over a lifetime, their concentrated upfront expense strains existing reimbursement models and raises ethical and policy questions regarding affordability and prioritization. Furthermore, the expansion of gene therapy into common diseases with large patient populations necessitates a recalibration of safety thresholds, regulatory frameworks, and long-term surveillance strategies.
- The gene therapy stands at a pivotal inflection point. The field has demonstrated undeniable clinical efficacy and technological robustness, yet its future impact will depend on the successful integration of scientific innovation with scalable manufacturing, sustainable economic models, adaptive regulatory oversight, and ethical stewardship. If these challenges are addressed through coordinated multidisciplinary efforts, gene therapy has the potential not only to redefine treatment paradigms across multiple disease domains but also to fundamentally reshape the future

of medicine by enabling durable, mechanism-based, and patient-centered interventions.

1.2. Recommendations

- ✓ To ensure the sustainable advancement and equitable integration of gene therapy into routine clinical practice, several strategic priorities should be addressed across scientific, clinical, regulatory, and policy domains.
- ✓ The continued investment in next-generation gene editing technologies is essential. Research efforts should prioritize the refinement of base editing, prime editing, and epigenome-modulating tools that offer enhanced precision and reduced genotoxic risk compared with nuclease-based systems. Parallel development of tissue-specific and immune-evasive delivery platforms, including engineered viral capsids, lipid nanoparticles, and non-viral vectors, will be critical for expanding in vivo applications beyond currently accessible organs and minimizing immunological barriers.
- ✓ Manufacturing innovation must be recognized as a central enabler of clinical translation rather than a downstream technical consideration. The adoption of closed, automated, and modular manufacturing systems should be accelerated to improve scalability, reduce costs, and ensure consistent product quality. Decentralized or point-of-care manufacturing models, where feasible, may significantly shorten treatment timelines and improve access, particularly for autologous cell therapies. Standardization of analytical assays and potency metrics across platforms will further enhance regulatory confidence and facilitate global harmonization.
- ✓ Long-term safety and effectiveness monitoring should remain a core component of gene therapy deployment. Robust post-marketing surveillance systems, international patient registries, and real-world evidence generation are necessary to detect late-emerging adverse events, assess durability of therapeutic benefit, and refine patient selection criteria. Integration of digital health technologies and biomarker-driven monitoring may reduce patient burden while improving data quality and completeness over extended follow-up periods.
- ✓ Sustainable economic and reimbursement frameworks must be developed to align innovation with affordability. Outcomes-based payment models, annuity-style reimbursement, and risk-sharing agreements between manufacturers and payers should be expanded and rigorously evaluated. Public-private partnerships and international funding mechanisms may play a critical role in supporting access to gene therapies in low- and middle-income countries, preventing the emergence of a global therapeutic divide.
- ✓ Regulatory agencies should continue to evolve adaptive, science-based frameworks that accommodate platform technologies, personalized therapies, and rapid iteration while

maintaining rigorous safety standards. Early and continuous dialogue between developers, regulators, clinicians, and patient representatives can streamline development pathways and ensure that regulatory decisions reflect both scientific evidence and patient priorities.

- ✓ Interdisciplinary education and workforce development are imperative. Clinicians, pharmacists, genetic counselors, and allied healthcare professionals must be adequately trained in gene therapy mechanisms, administration, toxicity management, and ethical considerations. Public engagement and transparent communication are equally important to foster informed consent, manage expectations, and build societal trust in genetic medicines.
- ✓ The recommendations emphasize that the future success of gene therapy will depend not only on scientific breakthroughs but also on coordinated systemic action. By addressing technological, economic, regulatory, and ethical dimensions in parallel, the gene therapy field can progress toward its ultimate objective: delivering safe, durable, and accessible genetic treatments that meaningfully improve patient outcomes on a global scale.

References

1. Cotrim, A. P., & Baum, B. J. (2008). Gene therapy: Some history, applications, problems, and prospects. *Toxicologic Pathology, 36*(1), 97-103.
2. Davies, B., Zhan, H., & Atkins, H. (2024). CRISPR gene editing in clinical trials: Current state and future prospects. *Nature Medicine, 30*(4), 891-903.
3. Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2024). Gene therapy clinical trials worldwide to 2024: An update. *The Journal of Gene Medicine, 26*(1), e3628.
4. Han, D., Xu, Z., Zhuang, Y., Ye, Z., & Qian, Q. (2021). Current progress in CAR-T cell therapy for hematological malignancies. *Journal of Cancer, 12*(2), 326-334.
5. Khan, M. I., Rafiq, S., & Khalid, S. (2024). Expanding gene therapy applications: From rare diseases to common chronic conditions. *Molecular Therapy, 32*(5), 1234-1248.
6. Kumar, S. R., Markusic, D. M., Biswas, M., High, K. A., & Herzog, R. W. (2016). Clinical development of gene therapy: Results and lessons from recent successes. *Molecular Therapy - Methods & Clinical Development, 3*, 16034.
7. Sulashvili, N., Davitashvili, M., Gorgaslidze, N., Gabunia, L., Beglaryan, M., Alavidze, N., Sulashvili, M. (2024). The scientific discussion of some issues of features and challenges of using of car-t cells in immunotherapy. Georgian Scientists, 6(4), 263–290. https://doi.org/10.52340/gs.2024.06.04.24
8. Lapteva, L., Purohit-Sheth, T., Serabian, M., & Puri, R. K. (2020). Clinical development and regulation of cell and gene therapies. *Cytotherapy, 22*(10), 594-602.
9. Leonard, A., & Tisdale, J. F. (2024). CRISPR-edited hematopoietic stem cells for sickle cell disease and β-thalassemia. *New England Journal of Medicine, 390*(3), 282-295.
10. Lu, Y., & Jiang, P. (2022). Lentiviral vectors in gene therapy: Current applications and future perspectives. *Molecular Therapy - Nucleic Acids, 28*, 734-748.

11. Rahmat, F., Joudeh, N., & Alshraideh, H. (2024). Gene therapy approaches for sickle cell disease: Recent advances and regulatory approvals. *Blood Articles, 58*, 101089.
12. Singh, M., Kumar, V., & Sharma, R. (2024). BCL11A targeting for hemoglobinopathies: From bench to bedside. *Trends in Molecular Medicine, 30*(2), 156-169.
13. Weinberg, M. S., Samulski, R. J., & McCown, T. J. (2013). Adeno-associated virus (AAV) gene therapy for neurological disease. *Neuropharmacology, 69*, 82-88.
14. Wirth, T., Parker, N., & Ylä-Herttuala, S. (2013). History of gene therapy. *Gene, 525*(2), 162-169.
15. Zhang, X., Wang, L., & Chen, Y. (2022). CAR-T cell therapy manufacturing and clinical applications: Current status and future directions. *Frontiers in Immunology, 13*, 923022.
16. Aphkhazava, D., Sulashvili, N., & Tkemaladze, J. (2025). Stem Cell Systems and Regeneration. Georgian Scientists, 7(1), 271–319. https://doi.org/10.52340/gs.2025.07.01.26.
17. High, K. A., & Roncarolo, M. G. (2019). Gene therapy. *New England Journal of Medicine*, 381(5), 455–464.
18. Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. *Science*, 346(6213), 1258096.
19. Urnov, F. D., Ronald, M., Holmes, M. C., & Gregory, P. D. (2010). Genome editing with engineered nucleases. *Nature Reviews Genetics*, 11(9), 636–646.
20. Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021). Viral vector platforms within the gene therapy landscape. *Signal Transduction and Targeted Therapy*, 6(1), 1–24.
21. Naldini, L. (2015). Gene therapy returns to centre stage. *Nature*, 526(7573), 351–360.
22. Esensten, J. H., Bluestone, J. A., & Lim, W. A. (2017). Engineering therapeutic T cells: From synthetic biology to clinical trials. *Annual Review of Pathology: Mechanisms of Disease*, 12, 305–330.
23. June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. *Science*, 359(6382), 1361–1365.
24. Sulashvili, N., Jadhav, R. D., Beglaryan, M., Gabunia, L., Gorgaslidze, N., Alavidze, N., … Robakidze, K. (2025). The scientific discussion of key issue aspects of immunopathogenesis and pharmacological properties and profiles in relation to adverse drug reactions challenges, focus on multidimensional drug-induced eosinophilia and systemic syndrome. Georgian Scientists, 7(3), 141–179. https://doi.org/10.52340/gs.2025.07.03.13.
25. Ylä-Herttuala, S. (2012). Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. *Molecular Therapy*, 20(10), 1831–1832.
26. Wang, D., Tai, P. W. L., & Gao, G. (2019). Adeno-associated virus vector as a platform for gene therapy delivery. *Nature Reviews Drug Discovery*, 18(5), 358–378.
27. Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., & Sadelain, M. (2017). Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. *Nature*, 543(7643), 113–117.
28. Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018). Gene therapy comes of age. *Science*, 359(6372), eaan4672.
29. Abel, T., & Gao, G. (2020). Overcoming barriers to clinical translation of AAV gene therapy. *Nature Medicine*, 26(6), 857–869.

30. Sulashvili, N., Patsia, L., El-Hakeem, A., Ayaan, S., Hizomi, A., Agarwal, S., & Sulashvili, M. (2025). Exploring The Gut-Brain Axis: The Role Of The Microbiome In Modulating Brain Function And Its Implications In Neurodegenerative Disorders Like Parkinson's And Alzheimer's And Pharmacotherapy Treatment Strategies. Georgian Scientists, 7(2), 329–353. https://doi.org/10.52340/gs.2025.07.02.32
31. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *New England Journal of Medicine*, 365(8), 725–733.
32. Raper, S. E., & Wilson, J. M. (2020). Gene therapy: Ethical and regulatory issues. *Annual Review of Medicine*, 71, 401–415.
33. Ghongadze, M., Pkhaladze, M., Sulashvili , N., & Pkhaladze, N. (2025). Tbilisi, Crispr/Cas9 Technology in Cancer Treatment: Current Applications and Perspectives. World of Medicine : Journal of Biomedical Sciences, 2(2), 71–76. Retrieved from https://wom.semanticjournals.org/index.php/biomed/article/view/300
34. Hoggatt, J., & Kiem, H. P. (2021). Gene therapy for inherited blood disorders: An evolving therapeutic paradigm. *Blood*, 138(22), 2213–2222.
35. Aphkhazava, D., Sulashvili, N., Maglakelidze, G., & Tkemaladze, J. (2025). Ageless Creatures: Molecular Insights into Organisms That Defy Aging. Georgian Scientists, 7(3), 346–396. https://doi.org/10.52340/gs.2025.07.03.24
36. Bhagat, M., Kamal, R., Sharma, J., Kaur, K., Sharma, A., Singh, T. G., Bhatia, R., & Awasthi, A. (2024). Gene Therapy: Towards a New Era of Medicine. AAPS PharmSciTech, 26(1), 17. https://doi.org/10.1208/s12249-024-03010-6
37. Zhang J, Li M, Liu M, Yu Q, Ge D, Zhang J. Metal–organic framework nanomaterials as a medicine for catalytic tumor therapy: Recent Advances. Nanomaterials. 2024;14(9):797.
38. Belete TM. The current status of gene therapy for the treatment of cancer. Biol: Targets Ther. 2021;15(null):67–77.
39. Belete TM. The current status of gene therapy for the treatment of cancer. Biologics. 2021;15:67–77.
40. Rashid RA, Ankathil R. Gene therapy: an updated overview on the promising success stories. Malays J Pathol. 2020;42(2):171–85.
41. Amador C, Shah R, Ghiam S, Kramerov AA, Ljubimov AV. Gene therapy in the anterior eye segment. Curr Gene Ther. 2022;22(2):104–31.
42. Alnasser SM. Review on mechanistic strategy of gene therapy in the treatment of disease. Gene. 2021;769:145246.
43. Tiwari S, Menghani E. Mode of viral and non-viral gene transfer: an overview. S. Tiwari and E. Menghani, mode of viral and non-viral gene transfer: an overview. International Journal of Advanced Research in Engineering and Technology. 2020;11(11).
44. Gupta K, Singh S, Garg KN. Gene therapy in dentistry: tool of genetic engineering. Revisited Arch Oral Biol. 2015;60(3):439–46.
45. Aphkhazava, D., Sulashvili, N., Egnatievi, I., Tupinashvili, T., & Nozadze, M. (2024). DYNAMIC TUMOR MICROENVIRONMENT THEORY: A MULTIFACETED APPROACH

TO TUMOR RESEARCH AND BIOCHEMISTRY. Scientific Journal „Spectri“, 9(1). https://doi.org/10.52340/spectri.2024.09.01.06

46. Dwivedi S, Purohit P, Mittal Y, Gupta G, Goel A, Verma RC, Khattri S, Sharma P, Misra S, Pant KK. Genetic engineering: towards gene therapy and molecular medicine. InOmics Technologies and Bio-Engineering. Academic Press; 2018. pp. 507-32.
47. Leidner R, Sanjuan Silva N, Huang H, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386(22):2112–9.
48. Dogbey DM, Torres VES, Fajemisin E, et al. Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy. Drug Deliv Transl Res. 2023;13(11):2719–38.
49. Wu X, He X, Liu F, et al. Development and clinical translation of ex vivo gene therapy. Comput Struct Biotechnol J. 2022;20:2986–3003.
50. Jayarajan V, Kounatidou E, Qasim W, Di W-L. *Ex vivo* gene modification therapy for genetic skin diseases—recent advances in gene modification technologies and delivery. Exp Dermatol. 2021;30(7):887–96.